Home - Invivoscribe

Cat #: 11000041

IGH + IGK B-Cell Clonality Assay MegaKit – ABI Fluorescence Detection

BACKGROUND Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products th...

View Product

Cat #: IGH Clonality

IGH Clonality Assay

Lymphoid cells are different from the other somatic cells in the body as during development, the antigen receptor genes in lymphoid cells undergo soma...

View Product

Cat #: A1010041

IGH DH1-6 – HEX

This product targets the diversity and joining regions of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010051

IGH DH7 – 6FAM

This product targets the diversity and joining regions of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010011

IGH FR1- 6FAM

This product targets the framework 1 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010101

IGH FR2 – 6FAM

This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010020

IGH FR2 – Unlabeled

This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010031

IGH FR3 – HEX

This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010030

IGH FR3 – Unlabeled

This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010061

IGH Framework 1 – 6FAM

This product targets the framework 1 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: 21010061

IGH Framework 1 (FR1) – 6FAM for ABI Fluorescence Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Cat #: 21010060

IGH Framework 1 (FR1) – Unlabeled for Gel Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Cat #: A1010091

IGH Framework 2 – 6FAM

This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010070

IGH Framework 2 – Unlabeled

This product targets the framework 2 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: 21010091

IGH Framework 2 (FR2) – 6FAM for ABI Fluorescence Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Cat #: 21010070

IGH Framework 2 (FR2) – Unlabeled for Gel Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Cat #: A1010081

IGH Framework 3 – HEX

This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: A1010080

IGH Framework 3 – Unlabeled

This product targets the framework 3 region of the human immunoglobulin heavy chain gene. ...

View Product

Cat #: 21010081

IGH Framework 3 (FR3) – HEX for ABI Fluorescence Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Cat #: 21010080

IGH Framework 3 (FR3) – Unlabeled for Gel Detection

Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selecti...

View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

All Products

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020 Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

All Products

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

October 30th, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma